Trius Therapeutics, Inc.
TSRX, a biopharmaceutical company focused on the discovery and
development of innovative antibiotics for life-threatening infections,
announced today that it has reached its enrollment objective of 658 patients
in the last of its two Phase 3 clinical trials of tedizolid phosphate (TR-701)
for the treatment of acute bacterial skin and skin structure infections
(ABSSSI).
The pivotal Phase 3 trial, designated ESTABLISH 2, examines the efficacy and
safety of a six-day course of tedizolid administered once a day versus a
10-day course of linezolid (Zyvox^®) administered twice a day in patients
recruited across sites in North and South America, Europe, Australia, New
Zealand and South Africa. For both tedizolid phosphate and linezolid, drug was
initially administered as an intravenous (IV) infusion with the option to
switch to oral therapy after the initial day of therapy.
Last year, Trius completed its ESTABLISH 1 study, testing the oral dosing of
tedizolid under the same trial design and endpoints as in ESTABLISH 2. The
trial achieved all primary and secondary efficacy outcomes and showed
significant safety and tolerability improvements versus linezolid.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in